Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · IEX Real-Time Price · USD
2.790
-0.060 (-2.11%)
Jul 19, 2024, 4:30 PM EDT - Market closed
Aytu BioPharma Revenue
Aytu BioPharma had revenue of $93.76M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $17.99M. In the fiscal year ending June 30, 2023, Aytu BioPharma had annual revenue of $107.40M with 11.10% growth.
Revenue (ttm)
$93.76M
Revenue Growth
-9.95%
P/S Ratio
0.18
Revenue / Employee
$625,053
Employees
150
Market Cap
16.66M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 107.40M | 10.73M | 11.10% |
Jun 30, 2022 | 96.67M | 31.04M | 47.29% |
Jun 30, 2021 | 65.63M | 38.00M | 137.52% |
Jun 30, 2020 | 27.63M | 20.31M | 277.47% |
Jun 30, 2019 | 7.32M | 3.66M | 100.00% |
Jun 30, 2018 | 3.66M | 438.53K | 13.61% |
Jun 30, 2017 | 3.22M | 659.15K | 25.72% |
Jun 30, 2016 | 2.56M | 2.30M | 878.85% |
Jun 30, 2015 | 261.78K | 202.85K | 344.23% |
Jun 30, 2014 | 58.93K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
China Jo-Jo Drugstores | 154.66M |
VBI Vaccines | 9.41M |
BIMI International Medical | 5.85M |
Lyra Therapeutics | 1.68M |
Talis Biomedical | 989.00K |
AYTU News
- 4 weeks ago - Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms - Accesswire
- 2 months ago - Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results - Accesswire
- 2 months ago - Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 - Accesswire
- 3 months ago - Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 - Accesswire
- 5 months ago - Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - Accesswire
- 5 months ago - Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024 - Accesswire
- 6 months ago - Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 - Accesswire
- 8 months ago - Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023 - Accesswire